期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 16, 期 10, 页码 1442-1450出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2010.04.009
关键词
Hematopoietic cell transplantation; Obesity; Outcomes; Acute myelogenous leukemia
资金
- National Cancer Institute (NCI) [U24-CA76518]
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI [5U01HL069294]
- NCI
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB
- Aetna
- American Society for Blood and Marrow Transplantation
- Amgen, Inc.
- Anonymous donation to the Medical College of Wisconsin
- Astellas Pharma US, Inc.
- Baxter International, Inc.
- Bayer HealthCare Pharmaceuticals
- Be the Match Foundation
- Biogen IDEC
- BioMarin Pharmaceutical, Inc.
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Canadian Blood and Marrow Transplant Group
- CaridianBCT
- Celgene Corporation
- CellGenix, GmbH
- Centers for Disease Control and Prevention
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex Inc.
- CytoTherm
- DOR BioPharma, Inc.
- Dynal Biotech, an Invitrogen Company
- Eisai, Inc.
- Enzon Pharmaceuticals, Inc.
- European Group for Blood and Marrow Transplantation
- Gamida Cell, Ltd.
- GE Healthcare
- Genentech, Inc.
- Genzyme Corporation
- Histogenetics, Inc.
- HKS Medical Information Systems
- Hospira, Inc.
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewery Co., Ltd.
- The Leukemia & Lymphoma Society
- Merck Company
- The Medical College of Wisconsin
- MGI Pharma, Inc.
- Michigan Community Blood Centers
- Millennium Pharmaceuticals, Inc.
- Miller Pharmacal Group
- Milliman USA, Inc.
- Miltenyi Biotec, Inc.
- National Marrow Donor Program
- Nature Publishing Group
- New York Blood Center
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics, Inc.
- Otsuka America Pharmaceutical, Inc.
- Pall Life Sciences
- Pfizer Inc
- Saladax Biomedical, Inc.
- Schering Corporation
- Society for Healthcare Epidemiology of America
- Soligenix, Inc.
- StemCyte, Inc.
- StemSoft Software, Inc.
- Sysmex America, Inc.
- THERAKOS, Inc.
- Thermogenesis Corporation
- Vidacare Corporation
- Vion Pharmaceuticals, Inc.
- ViraCor Laboratories
- ViroPharma, Inc.
- Wellpoint, Inc.
The incidence of excessive adiposity is increasing worldwide, and is associated with numerous adverse health outcomes. We compared outcomes by body mass index (BMI) for adult patients with acute myelogenous leukemia (AML) who underwent autologous (auto, n = 373), related donor (RD, n = 2041), or unrelated donor (URD, n = 1801) allogeneic myeloablative hematopoietic cell transplantation (HCT) using bone marrow or peripheral blood stem cells reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2004. Four weight groups by BMI (kg/m(2)) were defined: underweight <18 kg/m(2); normal 18-25 kg/m(2); overweight >25-30 kg/m(2); and obese >30 kg/m(2). Multivariable analysis referenced to the normal weight group showed an increased risk of death for underweight patients in the RD group (relative risk [RR], 1.92; 95% confidence interval [CI], 1.28-2.89; P = .002), but not in the URD group. There were no other differences in outcomes among the other weight groups within the other HCT groups. Overweight and obese patients enjoyed a modest decrease in relapse incidence, although this did not translate into a survival benefit. Small numbers of patients limit the ability to better characterize the adverse outcomes seen in the underweight RD but not the underweight URD allogeneic HCT patients. Obesity alone should not be considered a barrier to HCT. Biol Blood Marrow Transplant 16: 1442-1450 (2010) (c) 2010 American Society for Blood and Marrow Transplantation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
